Cipla grows national footprint with Mirren acquisition

Cipla-acquisitionCipla Medpro South Africa (Cipla Medpro), wholly owned subsidiary of Cipla Limited, India (Cipla), has announced plans to acquire a 100 percent stake in Mirren. Mirren is a local manufacturer and distributor of over-the-counter (OTC) pharma products and has been in operation for 35 years.

Cipla Medpro is South Africa’s fourth largest pharmaceutical company in the private sector.

The transaction is subject to the approval by the Competition Commission of South Africa.

Paul Miller, CEO of Cipla South Africa, said that once approved, the transaction will enhance Cipla’s current OTC portfolio, by adding Mirren’s well-established brands such as Broncol cough syrup, Coryx, Tensopyn and Ultimag. This deal will also increase Cipla’s local manufacturing footprint.

Lynton Lomas, director of Mirren, said: ‘The acquisition by Cipla will help ensure the continued growth achieved by Mirren brands over the past three years will be sustained. The wellbeing of Mirren’s dedicated staff was one of the biggest deciding factors during this process.’

Miller adds: ‘We foresee this transaction will aid Cipla greatly in future by improving the range of quality medication we are able to offer South Africans. Cipla aims to take full leverage of this proposed transaction to deliver on its ethos of “Caring for Life”, by providing quality, affordable medical products.’

Subscribe to our mailing list

* indicates required

Would you like to receive our FREE e-newsletter?

* indicates required